Omalizumab’s mechanism of IgE blockade differs from that of other biologics under investigation for food allergy, such as dupilumab (an anti-IL-4Rα antibody), which has shown a slower onset of desensitization in Phase 2 trials involving pediatric patients with peanut allergy (46). Here, IL4R is linked to food allergy.